Health Care • Industrial Specialties
$6.86 ▼ -0.40
(-5.51%)
MKT CAP: $192.7M • VOL: 201.2K
52W L $5 52W H $8
INGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $295.3M | $278.8M | $251.6M |
| YoY Revenue Growth % | +5.9% | +10.8% | — |
| Gross Profit | $154.3M | $154.7M | — |
| Gross Margin % | 52.2% | 55.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$30.2M | -$42.5M | -$109.4M |
| Operating Margin % | -10.2% | -15.3% | -43.5% |
| Net Income (GAAP) | $22.7M | $35.9M | $102.4M |
| EBITDA (Normalized) | -$28.2M | -$39.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$11.2M | $5.9M | -$3.2M |
| Capital Expenditures (CapEx) | $2.5M | $3.4M | — |
| Free Cash Flow (FCF) | -$13.7M | $2.6M | -$3.2M |
| FCF Margin % | -4.7% | 0.9% | -1.3% |
| Return on Invested Capital (ROIC %) | -27.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $103.7M | $113.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $192.2M | $173.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INGN.